RxDoctor Payments Data

Hannah Park, MD

Ophthalmology · Roswell, GANPI 1548657430

Payments from drug & device makers

$5,528in general payments, 2019–2025

Across 130 payments — averaging $42.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$728
  • AbbVie$568
  • Glaukos Corporation$557
  • Sun Pharmaceutical Industries Inc.$503
  • Genentech USA, Inc.$408
  • Bausch & Lomb Americas Inc.$398
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$5,510100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,528 in reported general payments places this provider in the 70th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$219,661
Medicare patients
577
Services billed
2,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine189$171,945
XiidraLifitegrast32$31,399
Cyclosporine62$25,649
LumiganBimatoprost51$21,443
TyrvayaVarenicline Tartrate19$15,530
RocklatanNetarsudil Mesylat/Latanoprost15$7,090
SimbrinzaBrinzolamide/Brimonidine Tart18$6,132
Prednisolone Acetate141$5,212
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol22$3,363
Latanoprost317$2,830
Tobramycin-DexamethasoneTobramycin/Dexamethasone45$1,761
Timolol Maleate108$1,241
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat70$1,033
Brimonidine Tartrate91$683
Dorzolamide Hcl38$628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$568$193,388240 claims
Bausch & Lomb Americas Inc.Xiidra$398$31,39932 claims
Oyster Point Pharma, Inc.Tyrvaya$123$15,53019 claims
Aerie Pharmaceuticals, Inc.Rocklatan$164$7,09015 claims
AlconSimbrinza$348$6,13218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Roswell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →